Treatment of Glioblastoma Multiforme with Radiotherapy and Concomitant and Adjuvant Temozolomide: Translation of Randomised Controlled Trial Evidence into Routine Clinical Practice-Reference-Cited by-同舟云学术

Treatment of Glioblastoma Multiforme with Radiotherapy and Concomitant and Adjuvant Temozolomide: Translation of Randomised Controlled Trial Evidence into Routine Clinical Practice

Published:2011-06 Issue:5 Volume:23 Page:372-373
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Herbert C.,Williams M.,Sawyer H.,Greenslade M.,Cornes P.,Hopkins K.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference3 articles.

1. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

2. MGMT gene silencing and benefit from temozolomide in glioblastoma;Hegi;N Engl J Med,2005

3. Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study;Sridhar;Clin Oncol (R Coll Radiol),2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Normalized Apparent Diffusion Coefficient in the Prognostication of Patients with Glioblastoma Multiforme;Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques;2016-01

2. Consider tumour type, as well as patient age and performance status, when selecting medical treatments for malignant glioma;Drugs & Therapy Perspectives;2015-04-25

3. Pharmacologic Therapies for Malignant Glioma: A Guide for Clinicians;CNS Drugs;2014-11-18

4. Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival;Journal of Cancer Research and Clinical Oncology;2012-05-27

5. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study;Journal of Neuro-Oncology;2012-03-18